CGH
GILD icon

Crossmark Global Holdings’s Gilead Sciences GILD Stock Holding History

Crossmark Global Holdings’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.4M Buy
541,294
+16,305
+3% +$2.15M 0.89% 14
2026
Q1 		$73.2M Sell
524,989
-26,933
-5% -$3.77M 1.08% 9
2025
Q4 		$67.7M Buy
551,922
+23,719
+4% +$2.88M 0.97% 14
2025
Q3 		$58.6M Buy
528,203
+15,182
+3% +$1.73M 0.88% 13
2025
Q2 		$56.9M Sell
513,021
-39,563
-7% -$4.21M 0.92% 14
2025
Q1 		$61.9M Buy
552,584
+12,364
+2% +$1.28M 1.09% 8
2024
Q4 		$49.9M Buy
540,220
+8,741
+2% +$787K 0.91% 15
2024
Q3 		$44.6M Buy
531,479
+34,381
+7% +$2.62M 0.79% 15
2024
Q2 		$34.1M Buy
497,098
+11,657
+2% +$778K 0.65% 20
2024
Q1 		$35.6M Sell
485,441
-26,656
-5% -$2.05M 0.68% 20
2023
Q4 		$41.5M Sell
512,097
-3,441
-0.7% -$268K 0.86% 10
2023
Q3 		$39.2M Buy
515,538
+3,176
+0.6% +$244K 0.89% 10
2023
Q2 		$39.4M Buy
512,362
+43,381
+9% +$3.46M 0.85% 9
2023
Q1 		$38.9M Buy
468,981
+120,885
+35% +$10M 0.92% 6
2022
Q4 		$29.9M Buy
348,096
+15,462
+5% +$1.22M 0.74% 15
2022
Q3 		$20.5M Buy
332,634
+3,844
+1% +$242K 0.57% 26
2022
Q2 		$20.3M Buy
328,790
+6,787
+2% +$420K 0.53% 29
2022
Q1 		$19.1M Buy
322,003
+91,879
+40% +$5.87M 0.43% 42
2021
Q4 		$16.7M Buy
230,124
+34,412
+18% +$2.37M 0.36% 59
2021
Q3 		$13.7M Buy
195,712
+46
+0% +$3.23K 0.32% 74
2021
Q2 		$13.5M Buy
195,666
+9,677
+5% +$646K 0.32% 72
2021
Q1 		$12M Buy
185,989
+177
+0.1% +$11.4K 0.3% 83
2020
Q4 		$10.8M Sell
185,812
-4,856
-3% -$293K 0.27% 86
2020
Q3 		$12M Sell
190,668
-7,695
-4% -$534K 0.34% 67
2020
Q2 		$15.3M Sell
198,363
-12,939
-6% -$992K 0.45% 36
2020
Q1 		$15.8M Sell
211,302
-4,011
-2% -$277K 0.57% 31
2019
Q4 		$14M Buy
215,313
+4,564
+2% +$297K 0.38% 61
2019
Q3 		$13.4M Sell
210,749
-5,624
-3% -$368K 0.39% 56
2019
Q2 		$14.6M Sell
216,373
-2,210
-1% -$145K 0.41% 47
2019
Q1 		$14.2M Buy
218,583
+6,174
+3% +$410K 0.4% 48
2018
Q4 		$13.3M Buy
212,409
+8,833
+4% +$617K 0.41% 46
2018
Q3 		$15.7M Buy
203,576
+519
+0.3% +$39.2K 0.4% 47
2018
Q2 		$14.4M Sell
203,057
-550
-0.3% -$38.8K 0.39% 48
2018
Q1 		$15.3M Sell
203,607
-22,187
-10% -$1.76M 0.4% 46
2017
Q4 		$16.2M Buy
225,794
+4,038
+2% +$307K 0.39% 48
2017
Q3 		$18M Buy
+221,756
New +$17M 0.46% 40
2016
Q3 		$18M Buy
+221,756
New +$18M 0.46% 40

Other funds holding GILD

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM

Crossmark Global Holdings's GILD Position: Q2 2026 in Review

Crossmark Global Holdings increased its Gilead Sciences (GILD) stake by 3.1% in Q2 2026, buying an estimated $2.15M and bringing the position to 541,294 shares worth $68.4M. The position accounts for 0.89% of the portfolio, ranked #14.

Crossmark Global Holdings first reported a position in GILD in Q3 2016 and has held it in 37 quarters since. The position peaked at $73.2M in Q1 2026. 348 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Crossmark Global Holdings held 541,294 shares of Gilead Sciences worth $68.4M as of Q2 2026.
  • Crossmark Global Holdings bought 16,305 Gilead Sciences shares in Q2 2026, an estimated $2.15M.
  • Gilead Sciences made up 0.89% of Crossmark Global Holdings's portfolio in Q2 2026, its #14 holding.
  • Crossmark Global Holdings first reported a position in Gilead Sciences in Q3 2016 and has held it in 37 quarters since.
  • Crossmark Global Holdings's Gilead Sciences position peaked at $73.2M in Q1 2026.
  • 348 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.